Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Doses of AbGn-168 in Psoriasis
NCT00848055 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 40
Last updated 2013-11-01
Summary
The general aim of the trial is to determine the safety, tolerability and pharmacologic profile of single escalating doses of AbGn-168 administered subcutaneously or intravenously to patients with chronic plaque psoriasis
Conditions
Interventions
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 intravenous infusion
single dose intravenous infusion
- DRUG
-
AbGn168 subcutaneous injection
single dose subcutaneous injection
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Boehringer Ingelheim · Boehringer Ingelheim
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
Eligibility
- Min Age
- 18 Years
- Max Age
- 65 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2008-12-31
- Primary Completion
- 2010-10-31
Countries
- United States
- Germany
Study Locations
More Related Trials
-
Safety and Efficacy of Adalimumab to Methotrexate and Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00235820 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Assess the Pharmacokinetics, Immunogenicity and Safety of Escalating Doses of BMS-188667 Given as a Single Intravenous Infusion to Patients With Psoriasis Vulgaris
NCT00277225 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Evaluate the Safety and Efficacy of Adalimumab in Subjects With Chronic Plaque Psoriasis and Nail Psoriasis
NCT02016482 ·Status: COMPLETED ·Phase: PHASE3
-
A Double Blind Study in Pediatric Subjects With Chronic Plaque Psoriasis, Studying Adalimumab vs. Methotrexate
NCT01251614 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Evaluate Apo805K1 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT01483924 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Investigate the Safety, Tolerability, Absorption, Distribution, Metabolism, and Elimination of RWJ-445380 Administered to Patients With Plaque Psoriasis
NCT00396422 ·Status: COMPLETED ·Phase: PHASE2
-
A Study Comparing the Safety and Efficacy of Two Dosing Regimens of ABT-874 to Placebo in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00570986 ·Status: COMPLETED ·Phase: PHASE3
-
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of ABBV-157 in Healthy Volunteers and in Participants With Chronic Plaque Psoriasis
NCT03922607 ·Status: COMPLETED ·Phase: PHASE1
-
Study of Two Dosing Schedules of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645905 ·Status: COMPLETED ·Phase: PHASE2
-
Apremilast in Palmo-Plantar Psoriasis
NCT02400749 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety Study of Two Doses of Apremilast (CC-10004) In Japanese Patients With Moderate-To-Severe Plaque-Type Psoriasis
NCT01988103 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of CC-90005 in Healthy Subjects and Subjects With Moderate to Severe Plaque-type Psoriasis
NCT02502188 ·Status: TERMINATED ·Phase: PHASE1
-
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of CC-90006 in Subjects With Mild to Moderate Plaque-type Psoriasis
NCT03337022 ·Status: COMPLETED ·Phase: PHASE1
-
ACT-128800 in Patients With Moderate to Severe Chronic Plaque Psoriasis
NCT01208090 ·Status: COMPLETED ·Phase: PHASE2
-
A Phase 3 Study in Participants With Moderate to Severe Psoriasis
NCT01474512 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy and Safety of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00237887 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3b Safety and Efficacy Study of Apremilast to Treat Moderate to Severe Plaque-plaque Psoriasis
NCT01690299 ·Status: COMPLETED ·Phase: PHASE3
-
Multicenter Study of the Safety and Efficacy of Adalimumab in Subjects With Moderate to Severe Chronic Plaque Psoriasis
NCT00645814 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Efficacy and Safety/Tolerability of Subcutaneous MK-3222 in Participants With Moderate-to-Severe Chronic Plaque Psoriasis (MK-3222-012)
NCT01936688 ·Status: WITHDRAWN ·Phase: PHASE3
-
Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis
NCT01384630 ·Status: COMPLETED ·Phase: PHASE2
-
A Dose Ranging Study of AIN457 in Patients With Moderate to Severe Chronic Plaque-type Psoriasis
NCT01071252 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Compare Efficacy and Safety of ABP 501 and Adalimumab (HUMIRA®) in Adults With Moderate to Severe Plaque Psoriasis
NCT01970488 ·Status: COMPLETED ·Phase: PHASE3
-
Study Evaluating Single Dose Of ILV-095 In Psoriasis Subjects
NCT01010542 ·Status: TERMINATED ·Phase: PHASE1
-
Single and Multiple Dose Escalation Study to Assess the Safety and Tolerability of CJM112 in Psoriasis
NCT01828086 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess S011806 (DC-806 or LY4100504) in Healthy Adult Participants and Participants With Chronic Plaque Psoriasis
NCT06808815 ·Status: COMPLETED ·Phase: PHASE1